efegatran has been researched along with mci 9038 in 12 studies
| Studies (efegatran) | Trials (efegatran) | Recent Studies (post-2010) (efegatran) | Studies (mci 9038) | Trials (mci 9038) | Recent Studies (post-2010) (mci 9038) |
|---|---|---|---|---|---|
| 43 | 3 | 0 | 1,087 | 83 | 349 |
| Protein | Taxonomy | efegatran (IC50) | mci 9038 (IC50) |
|---|---|---|---|
| Prothrombin | Homo sapiens (human) | 0.22 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 7 (58.33) | 18.2507 |
| 2000's | 5 (41.67) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Andrade-Gordon, P; Costanzo, MJ; Hecker, LR; Kauffman, JA; Krishnan, R; Lewis, JM; Maryanoff, BE; Schott, MR; Tulinsky, A; Yabut, SC; Zhang, HC | 1 |
| Das, J; Kimball, SD; Lau, WF; Ogletree, ML; Reid, JA; Roberts, DG; Schumacher, WA; Seiler, SM; Wang, TC | 1 |
| Chang, CY; Chong, S; Das, J; Hall, SE; Han, WC; Iwanowicz, E; Kimball, SD; Lin, J; Malley, MF; Moquin, RV; Ogletree, ML; Reid, JA; Roberts, DG; Sack, JS; Schumacher, WA; Seiler, SM; Wang-Iverson, DB | 1 |
| Almond, HR; Andrade-Gordon, P; Corcoran, TW; Costanzo, MJ; de Garavilla, L; Giardino, EC; Haertlein, BJ; Hecker, LR; Kauffman, JA; Lewis, JM; Maryanoff, BE; Schott, MR; Yabut, SC; Zhang, HC | 1 |
| Callas, DD; Fareed, J | 1 |
| Callas, DD; Fareed, J; Hoppensteadt, D | 1 |
| Kleiman, NS | 1 |
| Verstraete, M | 1 |
| Deinum, J; Elg, M; Gustafsson, D | 1 |
| Naylor-Olsen, AM; Sanderson, PE | 1 |
| Adams, TE; Everse, SJ; Mann, KG | 1 |
4 review(s) available for efegatran and mci 9038
| Article | Year |
|---|---|
Clinical trials of conjunctive anticoagulant strategies in thrombolysis.
Topics: Anticoagulants; Antithrombins; Arginine; Blood Platelets; Clinical Trials as Topic; Epoprostenol; Heparin; Hirudin Therapy; Hirudins; Humans; Myocardial Infarction; Oligopeptides; Peptide Fragments; Pipecolic Acids; Platelet Aggregation Inhibitors; Randomized Controlled Trials as Topic; Recombinant Proteins; Sulfonamides; Thrombin; Thrombolytic Therapy | 1996 |
Modulating platelet function with selective thrombin inhibitors.
Topics: Administration, Oral; Adult; Animals; Antithrombins; Arginine; Blood Platelets; Boron Compounds; Clinical Trials as Topic; Dogs; Drug Evaluation, Preclinical; Glycine; Hirudin Therapy; Hirudins; Humans; Naphthalenes; Oligopeptides; Peptide Fragments; Pipecolic Acids; Piperidines; Recombinant Proteins; Sulfonamides; Thrombin | 1996 |
Thrombin inhibitor design.
Topics: Anticoagulants; Antithrombins; Arginine; Binding Sites; Dipeptides; Drug Design; Humans; Models, Molecular; Oligopeptides; Pipecolic Acids; Piperidines; Platelet Aggregation Inhibitors; Structure-Activity Relationship; Sulfonamides; Thrombin | 1998 |
Direct thrombin inhibitors in acute coronary syndromes: principal results of a meta-analysis based on individual patients' data.
Topics: Angina, Unstable; Antithrombins; Arginine; Glycine; Heparin; Hirudin Therapy; Hirudins; Humans; Myocardial Infarction; Oligopeptides; Peptide Fragments; Pipecolic Acids; Piperidines; Randomized Controlled Trials as Topic; Recombinant Proteins; Sulfonamides; Survival Rate; Thrombin | 2002 |
8 other study(ies) available for efegatran and mci 9038
| Article | Year |
|---|---|
Potent thrombin inhibitors that probe the S1 subsite: tripeptide transition state analogues based on a heterocycle-activated carbonyl group.
Topics: Amino Acid Sequence; Animals; Arginine; Binding Sites; Cattle; Crystallography, X-Ray; Guanidines; Humans; Molecular Sequence Data; Molecular Structure; Oligopeptides; Peptides; Pipecolic Acids; Protein Binding; Serine Proteinase Inhibitors; Sulfonamides; Thiazoles; Thrombin; Trypsin Inhibitors | 1996 |
Thrombin active site inhibitors: chemical synthesis, in vitro and in vivo pharmacological profile of a novel and selective agent BMS-189090 and analogues.
Topics: Animals; Binding Sites; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Design; Drug Evaluation, Preclinical; Fibrinolytic Agents; Humans; Mice; Nipecotic Acids; Rats; Serine; Serine Proteinase Inhibitors; Structure-Activity Relationship; Substrate Specificity; Thrombin; Thrombosis | 2002 |
Molecular design and structure--activity relationships leading to the potent, selective, and orally active thrombin active site inhibitor BMS-189664.
Topics: Administration, Oral; Animals; Binding Sites; Crystallography, X-Ray; Dipeptides; Disease Models, Animal; Dogs; Drug Design; Drug Evaluation, Preclinical; Fibrinolytic Agents; Humans; Inhibitory Concentration 50; Macaca fascicularis; Mice; Serine Proteinase Inhibitors; Structure-Activity Relationship; Sulfonamides; Thrombin; Thrombosis | 2002 |
In-depth study of tripeptide-based alpha-ketoheterocycles as inhibitors of thrombin. Effective utilization of the S1' subsite and its implications to structure-based drug design.
Topics: Animals; Anticoagulants; Binding Sites; Cattle; Crystallography, X-Ray; Dogs; Drug Design; Electrocardiography; Fibrinolytic Agents; Guinea Pigs; Humans; Hydrogen-Ion Concentration; Hypotension; In Vitro Techniques; Ketones; Models, Molecular; Molecular Structure; Oligopeptides; Platelet Aggregation; Rabbits; Stereoisomerism; Structure-Activity Relationship; Thiazoles; Thrombin; Trypsin; Venous Thrombosis | 2005 |
Direct inhibition of protein Ca by site directed thrombin inhibitors: implications in anticoagulant and thrombolytic therapy.
Topics: Antifibrinolytic Agents; Antithrombin III; Antithrombins; Aprotinin; Arginine; Binding Sites; Boron Compounds; Enzyme Activation; Fibrinolysis; Heparin; Hirudins; Humans; Oligopeptides; Peptide Fragments; Pipecolic Acids; Protein C; Recombinant Proteins; Sulfonamides; Thrombin | 1995 |
Comparative studies on the anticoagulant and protease generation inhibitory actions of newly developed site-directed thrombin inhibitory drugs. Efegatran, argatroban, hirulog, and hirudin.
Topics: Amino Acid Sequence; Anticoagulants; Antithrombins; Arginine; Endopeptidases; Feedback; Hirudins; Humans; Molecular Sequence Data; Oligopeptides; Peptide Fragments; Pipecolic Acids; Recombinant Proteins; Sulfonamides | 1995 |
The importance of enzyme inhibition kinetics for the effect of thrombin inhibitors in a rat model of arterial thrombosis.
Topics: Amino Acid Chloromethyl Ketones; Animals; Anticoagulants; Arginine; Azetidines; Benzylamines; Carotid Artery Thrombosis; Dose-Response Relationship, Drug; Fibrinolytic Agents; Glycine; Hemodynamics; Heparin; Hirudin Therapy; Hirudins; Kinetics; Male; Oligopeptides; Partial Thromboplastin Time; Peptide Fragments; Pipecolic Acids; Piperidines; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Sulfonamides; Thrombin; Thrombin Time | 1997 |
Predicting the pharmacology of thrombin inhibitors.
Topics: Anticoagulants; Arginine; Azetidines; Benzylamines; Blood Coagulation; Computer Simulation; Dose-Response Relationship, Drug; Glycine; Hirudins; Humans; Kinetics; Models, Cardiovascular; Oligopeptides; Peptide Fragments; Pipecolic Acids; Recombinant Proteins; Sulfonamides; Thrombin | 2003 |